Table 1.

Prevalence and temporal trends of potential macrolide and quinolone resistance-associated mutations in Mycoplasma genitalium in St. Petersburg, Russia

Mutations	No. of MG-positive samples* with mutations (CI95%)			P trend
	2007–2008 (n=21)	2013–2017 (n=64)	2018–2020 (n=60)
Macrolide resistance-associated mutations	0 (0 (0 to 15.5))	5 (7.8 (3.4 to 17.0))	15 (25.0 (15.8 to 37.2))	0.0009
Quinolone resistance-associated mutations	0 (0 (0 to 15.5))	5 (7.8 (3.4 to 17.0))	8 (13.3 (6.9 to 24.2))	0.0605
Macrolide plus quinolone resistance-associated mutations	0 (0 (0 to 15.5))	2 (3.1 (0.6 to 10.7))	6 (10.0 (4.7 to 20.1))	0.0447

*Cervicovaginal swab specimens from women and urethral swab specimens (also some few urine specimens) from men.